How does musculoskeletal care device sales work?
Zimmer Biomet Holdings, Inc designs and sells medical devices used in musculoskeletal care. Its portfolio includes products used in joint replacement and other orthopedic procedures. The company sells into healthcare providers and surgical settings. It operates at large-cap scale in the U.S. public markets.
Do margins and cash cover the debt?
FundamentalsFor 2025 (reported in USD), Zimmer Biomet posted EBIT of about USD 1.10 billion alongside depreciation and amortization of roughly USD 1.09 billion, with capex of USD 224.5 million. Total debt at year-end was USD 587.1 million.
Across the last twelve months, profitability metrics show a 70.03% gross margin, a 14.02% operating margin, and a 9.05% net profit margin, with ROE at 6.01%. The same period also shows a cash flow proxy of about USD 1.84 billion.
Does the price match fair value expectations?
DCF / MultiplesAt USD 92.07, the current price sits below the DCF-based fair value range implied by weaker-
Valuation allows for durability
TakeawayThe balance sheet looks workable if cash stays reliable. Debt is not large on paper, but net debt is meaningful. Durability depends on keeping cash conversion intact. If cash weakens, leverage pressure becomes the central risk. With today’s price, the valuation leaves room for that durability.